Patents Examined by Bruce R. Campell
  • Patent number: 7645456
    Abstract: The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: January 12, 2010
    Assignee: Sanofi Pasteur Biologics Co.
    Inventors: Richard A. Weltzin, Thomas P. Monath
  • Patent number: 7534435
    Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.
    Type: Grant
    Filed: April 26, 2006
    Date of Patent: May 19, 2009
    Assignee: Tripep AB
    Inventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
  • Patent number: 7510868
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: March 31, 2009
    Inventors: Paul Harden, Terry Hermiston, Irene Kuhn
  • Patent number: 7442550
    Abstract: A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the group consisting of: a peptide comprising the cyt domain of the envelope protein of the human endogenous retrovirus, HERV-W; a peptide comprising amino acids 448-538 of SEQ ID NO: 1; and a peptide comprising a sequence having, for any series of 20 amino acids, at least 80% identity with amino acids 448-538 of SEQ ID NO: 1. Detection is established by the fusogenic power of the polypeptide, which is demonstrated by syncytia formation.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: October 28, 2008
    Assignees: Biomerieux, Institut National de la Sante et de la Recherche Medicale
    Inventors: Francois Mallet, Francois-Loic Cosset, Jean-Luc Blond, Dimitri Lavillette, Olivier Bouton, Alessia Ruggieri
  • Patent number: 7439041
    Abstract: Peptide reagents that interact preferentially with the PrPsc form of the prion protein are described. Methods of using the reagents or antibodies to the reagents for detection, diagnosis, purification, therapy and prophylaxis for prions and prion-associated diseases are also described.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: October 21, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Melissa D. Michelitsch, Celine Y-H. Hu
  • Patent number: PP21118
    Abstract: A new and distinct cultivar of Petunia plant named ‘MP3’, characterized by its compact and outwardly spreading plant habit; freely and continuous branching habit; small leaf size; numerous small dark violet-colored flowers; and resistance to Botrytis and Powdery Mildew.
    Type: Grant
    Filed: September 29, 2002
    Date of Patent: June 29, 2010
    Assignee: NuFlora International Pty. Ltd.
    Inventor: Graham Noel Brown
  • Patent number: PP21862
    Abstract: A new and distinct Miniature Rose plant having attractive Red flowers.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: April 12, 2011
    Assignee: Nor'East Miniature Roses, Inc.
    Inventor: John M. Saville
  • Patent number: RE47177
    Abstract: Provided are compositions comprising recombinant DNA polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for enhanced single molecule sequencing. Such properties include increased resistance to photodamage, and can also include enhanced metal ion coordination, reduced exonuclease activity, reduced reaction rates at one or more steps of the polymerase kinetic cycle, decreased branching fraction, altered cofactor selectivity, increased yield, increased thermostability, increased accuracy, increased speed, increased readlength, and the like. Also provided are nucleic acids which encode the polymerases with the aforementioned phenotypes, as well as methods of using such polymerases to make a DNA or to sequence a DNA template.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: December 25, 2018
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Satwik Kamtekar, Arek Bibillo, Keith Bjornson, Fred Christians, Colleen Cutcliffe, Jeremiah Hanes, Lei Jia, Walter Lee, Erik Miller, Pranav Patel
  • Patent number: RE47222
    Abstract: Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from: the polypeptide sequences of SEQ ID 1-44 or sub-sequences from these sequences, the sub-sequences having 7 amino acids or more; or from polypeptide sequences having 85% homology or more with one or more of the above sequences and contained in one or more of the following databases: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource (PIR), Protein Research Foundation (PRF), or CDS translations of these.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Pep Tcell, Ltd.
    Inventors: Gregory Alan Stoloff, Wilson Romero Caparros-Wanderley
  • Patent number: RE47428
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: June 11, 2019
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Les A. Dakin, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • Patent number: RE47437
    Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: June 18, 2019
    Assignee: Akebia Therapeutics, Inc.
    Inventors: Richard Masaru Kawamoto, Shengde Wu, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer, Namal C. Warshakoon
  • Patent number: RE47439
    Abstract: The invention relates to an improved method for making agarose coated, agarose beads which contain cells. The method which is preferably automated, involves placing manufactured beads in a sample of mineral oil at a temperature gradient, such that the temperature drops as the bead moves through the oil. Preferably, a “trumpet tool” and a “straw tool” are employed in the method.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: June 18, 2019
    Inventors: Lawrence Gazda, Melissa Laramore, Timothy Hamilton, Barry Smith
  • Patent number: RE47471
    Abstract: Heat-stable oligomeric recombinant polypeptides, presenting at least one antigenic epitope of the pre-fusion Respiratory Syncytial Virus (RSV) F protein, comprising the RSV F protein ectodomain, functionally deleted in the HRB region, transmembrane and cytoplasmic domains replaced with a heterologous trimerization domain, and absent two functional multibasic furin cleavage sites, are useful as antigenic components in immunogenic compositions useful in methods of inducing an immune response and vaccinate against RSV infections.
    Type: Grant
    Filed: March 26, 2016
    Date of Patent: July 2, 2019
    Assignee: Mucosis B.V.
    Inventors: Cornelis Alexander Maria de Haan, Petrus Josephus Marie Rottier, Bert Jan Haijema
  • Patent number: RE47528
    Abstract: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: July 23, 2019
    Inventors: Frank Niehaus, Jürgen Eck, Renate Schulze, Michael Krohn
  • Patent number: RE47666
    Abstract: Herbicide combinations comprising an effective amount of components (A) and (B), where component (A) is/are one or more herbicides of the formula (I) or salts thereof, in which R1 is H or a group of the formula CZ1Z2Z3, where Z1, Z2 and Z3 are as defined in claim 1, R2 and R3 are each H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl having in each case up to 4 carbon atoms or acyl, R4 is H, (C1-C6)-alkyl or (C1-C6)-alkoxy; R5, R6, R7 and R8 are each H, (C1-C4)-alkyl, (C1-C3)-haloalkyl, halogen, (C1-C3)-alkoxy, (C1-C3)-haloalkoxy or cyano; A is CH2 or O or a direct bond, and the component (B) is one or more herbicides from the group of compounds consisting of (B1) thiencarbazone, tembotrione, SYN-523, pyroxsulam, penoxsulam, SYN-449, (B2) pyrasulfotole, trifloxysulfuron, saflufenacil, aminopyralid, ethofumesate, aminocyclopyrachlor and (B3) pyroxasulfone (KIH-485) are suitable for controlling harmful plants or for regulating the growth of plants.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: October 29, 2019
    Inventors: Erwin Hacker, Martin Hess, Martin Jeffrey Hills, Georg Bonfig-Picard, Thomas Auler
  • Patent number: RE47838
    Abstract: Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 4, 2020
    Inventors: Jonathan S. Wall, Timothy E. Sparer, Stephen J. Kennel
  • Patent number: RE47873
    Abstract: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block and fill lumens and spaces. The embolic compositions can be used as liquid embolic agents and crosslinked in situ or as preformed embolic articles, such as microspheres.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: February 25, 2020
    Inventors: Dennis W. Goupil, Hassan Chaouk, Troy Holland, Bruktawit T. Asfaw, Stephen D. Goodrich, Lucas Latini
  • Patent number: RE47885
    Abstract: Described herein are cannabidiol prodrugs used in pharmaceutical compositions as well as microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 3, 2020
    Assignee: Zynerba Pharmaceuticals, Inc.
    Inventors: Audra Lynn Strinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffrey Lynn Howard, Dana Carmel Hammel
  • Patent number: RE47972
    Abstract: The invention relates to Inter-alpha inhibitor proteins (I?Ip). The invention further relates to processes for purification of I?Ip compositions and their use for treatment of human diseases such as sepsis and septic shock, rheumatoid arthritis, cancer and infectious diseases.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 5, 2020
    Assignee: ProThera Biologics, Inc.
    Inventors: Yow-Pin Lim, Djuro Josic, Douglas C. Hixson
  • Patent number: RE47983
    Abstract: Provided herein are compositions and methods for identifying or quantitating one or more analytes in sample. The composition can comprise an affinity molecule reversibly conjugated to a label moiety via a double-stranded nucleic acid linker or via an adaptor molecule. The affinity molecule and the label moiety can be linked to different strands of the double-stranded nucleic acid linker. Compositions can be used in any biological assays for detection, identification and/or quantification of target molecules or analytes, including multiplex staining for molecular profiling of individual cells or cellular populations. For example, the compositions can be adapted for use in immunofluorescence, fluorescence in situ hybridization, immunohistochemistry, western blot, and the like.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: May 12, 2020
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Xiaohu Gao, Pavel Zrazhevskiy